Memantine Merz (Memantine Hydrochloride)

Memantine is an NMDA receptor antagonist used in the symptomatic treatment of Alzheimer’s disease.

• Moderate to severe Alzheimer’s disease: improves cognition, functional abilities and behavioral symptoms in affected patients.
• Mild‑to‑moderate Alzheimer’s disease (off‑label): may provide modest symptomatic benefit.
• Dementia associated with Alzheimer’s disease: helps stabilize cognitive decline and daily functioning.

• Memantine acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel at a site distinct from the glutamate binding site, it reduces excessive calcium influx caused by pathological glutamate stimulation, thereby limiting excitotoxic neuronal injury while preserving normal synaptic transmission.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Confusion: transient disorientation.
• Fatigue: feeling unusually tired.
• Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring immediate medical attention.
• Cardiac arrhythmia: irregular heart rhythms.
• Stevens‑Johnson syndrome: severe skin reaction with blistering.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Severe skin reactions: rash, erythema, or exfoliative dermatitis.
• Suicidal thoughts: emergence of suicidal ideation or behavior.

Memantine should be used with caution in specific clinical situations.

• Renal impairment: dose adjustment may be required based on kidney function.
• History of seizures: monitor closely for increased seizure activity.
• Cardiovascular disease: assess blood pressure regularly during therapy.
• Concurrent use of other NMDA antagonists: avoid duplication to prevent excess CNS depression.
• Pregnancy and lactation: safety not established; prescribe only if potential benefit outweighs risk.
• Store at room temperature: keep in the original container, protect from moisture and light.

Memantine may interact with several medicines; monitoring is advised.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neurotoxicity.
• Other NMDA antagonists (e.g., ketamine): risk of severe central nervous system depression.
• Strong CYP450 inducers (e.g., carbamazepine, rifampicin): may reduce memantine plasma concentrations.
• High‑dose anticholinergics: may exacerbate cognitive impairment.
• Alcohol: can intensify dizziness and confusion.

Moderate Interactions (Monitor Closely)

• Diuretics (e.g., furosemide): may increase risk of hypotension.
• Antihypertensives: additive blood‑pressure‑lowering effect.
• Anticholinergic agents: may counteract memantine’s cognitive benefits.
• CNS depressants (e.g., benzodiazepines): enhanced sedation and drowsiness.
• Vaccines: monitor immune response, although no direct pharmacokinetic interaction is known.